Related Experiment Video

Updated: Apr 20, 2026

Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging
10:04

Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging

Published on: October 20, 2017

14.3K

Natural history and therapy of AL cardiac amyloidosis

Martha Grogan1, Angela Dispenzieri

  • 1Division of Cardiology, Department of Medicine, Mayo Clinic, Rochester, MN, USA, grogan.martha@mayo.edu.

Heart Failure Reviews
|December 3, 2014
PubMed

Insights

Immunoglobulin light chain amyloidosis (AL) significantly impacts survival, especially with cardiac involvement. Effective treatment targeting the plasma cell clone is crucial for improving outcomes in patients with cardiac AL.

Area of Science:

  • Cardiology
  • Hematology
  • Oncology

Background:

  • Immunoglobulin light chain amyloidosis (AL) is a plasma cell disorder where amyloid deposits in organs, primarily the heart.
  • Cardiac involvement significantly dictates the natural history and prognosis of AL amyloidosis.
  • Symptomatic heart failure in cardiac AL patients has a poor prognosis without effective treatment of the underlying plasma cell disorder.

Purpose of the Study:

  • To review the natural history, diagnosis, and management of cardiac AL amyloidosis.
  • To highlight the prognostic significance of cardiac biomarkers and arrhythmias.
  • To discuss current and emerging therapeutic strategies for improving survival in cardiac AL.

Main Methods:

  • Review of existing literature on cardiac AL amyloidosis.
  • Analysis of prognostic factors including cardiac biomarkers (NT-proBNP, troponin).
  • Evaluation of treatment strategies, including chemotherapy and stem cell transplantation.

Main Results:

  • Cardiac involvement is the primary determinant of survival in AL amyloidosis.
  • Cardiac biomarkers are powerful predictors of prognosis and guide treatment decisions.
  • Early diagnosis and effective treatment of the plasma cell clone are essential for improving survival.

Conclusions:

  • Cardiac AL amyloidosis requires a multi-faceted approach focusing on treating the underlying plasma cell disorder.
  • Advances in disease-modifying therapies have improved overall survival, emphasizing the need for earlier diagnosis and intervention.
  • Supportive care for heart failure is limited, and certain cardiovascular medications should be avoided.

More Related Videos

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis06:33

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis

Published on: June 9, 2018

8.2K
Performing and Processing FNA of Anterior Fat Pad for Amyloid09:41

Performing and Processing FNA of Anterior Fat Pad for Amyloid

Published on: October 30, 2010

56.6K

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
724
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
13.2K
Amyloid Fibrils03:03

Amyloid Fibrils

7.0K
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
939
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
812
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
811